On today programme we have Zak Mir our resident charter talking with Alan Green, we are sure Alan needs no introduction. He works on the VOX podcast, is a partner in @NovusComms Financial Social Media and Digital Communications for Small Caps.
Today the guys cover the announcement from Open Orphan PLC (ORPH.L) Testing of anti-viral for treating COVID-19. Dublin-listed pharma services company Open Orphan has begun testing an anti-viral treatment for COVID-19 through its London-based subsidiary Hvivo.
The testing is being carried out on behalf of Nearmedic International, a specialist pharmaceutical, a biotechnological and medical company headquartered in Moscow.
Tiziana Life Sciences (TILS.L) is based around developing treatment from human molecules, Alan goes into more depth about the company. Once the lockdown is lifted we may get a second wave, hopefully we will have a treatment in place.
Tiziana Life Sciences is a dual-listed (NASDAQ: TLSA, AIM: TILS) clinical-stage biotechnology company that specializes in the developing transformative therapies for inflammatory diseases and cancer-related to the liver. Our clinical pipeline includes drug assets for NASH, Crohn’s, and hepatocellular carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.
Bidstack Group (BIDS.L) AIM-quoted native in-game advertising company serving the global video games industry across multiple platforms.
Bidstack is a provider of native in-game advertising that is dynamic, targeted and automated, serving the global video games industry across multiple platforms. Its proprietary technology is capable of inserting adverts into natural advertising space within video games. The key benefit of native in-game advertising over non-native variants (e.g. video rolls and banner ads) is that it appears authentic and “natural” to the environment and does not adversely affect the gamer’s experience.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned